Immunotherapy is preferred initial treatment for majority of patients
Timing of adjuvant immunotherapy unclear for maximum overall survival
Tumor-infiltrating lymphocytes and natural killer cells
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy